Tag

Recurring Revenue

All articles tagged with #recurring revenue

business11 days ago•4 min saved

Brunswick leans on AI tech and boat clubs to shore up sales

Brunswick Corp., parent of Sea Ray and Boston Whaler, is betting on autonomous docking and other marine technology plus its Freedom Boat Club membership to offset weak new-boat demand. About 60% of earnings already come from aftermarket or recurring revenue, and the company aims for $7–$8 billion in revenue by 2030 with 10%–13% operating margins and $8–$12 per share in earnings, while expanding Navico electronics and reducing China-sourced parts to cut supply-chain risk.

via CNBC|

#autonomous-docking #brunswick #business

finance13 days ago•43 min saved

Nebius Expands AI Data-Center Push With 5 GW Capacity Target

Nebius NBIS has been steadily lifting its contracted-power guidance for 2026, moving from 3 GW to 4 GW and now aiming for 5 GW as it adds data centers across North America and Europe. The surge comes with big deals, including Meta’s cloud-compute arrangement that could deliver roughly $5 billion in annual recurring revenue once online, potentially lifting Nebius toward about $9 billion in ARR by year-end. Q2 revenue rose to $582.3 million, up 454% year over year, and the company is financing buildouts through prepayments and debt (notably $4 billion in private convertible notes) while remaining cash-flow negative and reliant on contract momentum to convert revenue in the coming years.

via Currently.com|

#contracted-power #finance #gigawatts

markets1 month ago•6 min saved

IBM's Long Road Back: How History Maps Its Potential Recovery

IBM stock has fallen about 22% in a month and sits roughly 37% below its 52-week high after a Q2 miss and a cut to full-year revenue guidance, raising questions about whether demand weakness is temporary or structural. Historically, IBM’s peak-to-trough drops during shocks average about 16% with a 37% worst plunge in 2020, and recoveries have ranged from ~5 months to as long as 9 years. The company has shifted toward software with roughly 45% of revenue and a large recurring software base, plus a strong z-series mainframe, but it remains exposed to enterprise IT spending cycles. For investors, the key risk management takeaway is disciplined position sizing and diversification to withstand another shock.

via Trefis|

#ibm #market-shocks #markets

opinion3 months ago•18 min saved

Space as a Service: Invest in Networks, Not Just Rockets

The article argues that space is shifting from one-off hardware bets to a networked, service-based model. With thousands of satellites and fleets like Starlink, space infrastructure now provides ongoing connectivity, Earth observation, and secure communications. Investors should focus on companies that own or operate space networks and deliver recurring revenue (not just single-component suppliers), diversify across the value chain to reduce risk, and push for clear regulatory rules to enable long-term planning as the space economy could reach trillions by 2035.

via SpaceNews|

#investment-strategy #opinion #recurring-revenue

markets5 months ago•11 min saved

Micron’s AI-fueled Rally Faces Inevitable Reversion to Mean

The analysis argues Micron’s current stock surge reflects a temporary, cyclical memory-demand spike driven by AI, not lasting growth. As memory capacity expands, margins and earnings are likely to retrace, making MU overvalued versus secular growers with recurring revenues (e.g., data-center REITs like Equinix) and utilities. The piece highlights how capacity expansions have historically crushed cyclical highs, and Micron’s own capex plan will boost supply further, supporting a return to equilibrium rather than permanent gains. Investors should rotate from MU’s immediate-revenue burst to companies with durable, recurring revenue.

via Seeking Alpha|

#ai-infrastructure #data-centers #markets

business2 years ago•3 min saved

Novavax and Moderna Compete in Dual COVID-19/Flu Vaccine Trials

Novavax, a smaller rival to Moderna and Pfizer in the COVID-19 vaccine market, may have a better chance of gaining market share with its updated coronavirus vaccine. As the vaccine landscape shifts to a commercial model, Novavax could carve out a market share by rapidly delivering doses to customers. This opportunity is crucial as the coronavirus is expected to stay, creating a potential market for annual vaccine sales. Novavax's presence in the vaccine marketplace now could also position it well for a potential combined flu/coronavirus vaccine product in the future. Investors should monitor Novavax's progress and consider the long-term rewards of its vaccine innovation.

via The Motley Fool|

#business #covid-19-vaccines #market-share